# BioGenerator

> BioGenerator is a VC fund in St Louis backing Biotechnology and Health Care. See 79 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: St Louis, United States
- Total investments: 79
- Last investment: Aug 2023
- Lead investor: 32%
- Last fund: May 2010
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/biogenerator
- X (Twitter): http://twitter.com/BioGeneratorSTL
- Website: http://www.biogenerator.org

BioGenerator is a VC fund in St Louis focused on Biotechnology and Health Care. The BioGenerator, the non-profit venture development organization of BioSTL, facilitates the formation of successful, sustainable bioscience companies in the St. Louis region. It provides start-up bioscience companies with pre-seed and seed investment funds, shared lab space with specialized equipment, and in-depth management support.

## Contacts

5 contacts available for BioGenerator. Shizune tracks 11 team members at BioGenerator. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/biogenerator?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 38 | 48% |
| Health Care | 30 | 38% |
| Agriculture | 10 | 13% |
| Life Science | 9 | 11% |
| Medical Device | 8 | 10% |

65 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 32 | 41% |
| Series A | 12 | 15% |
| Funding Round | 12 | 15% |
| Grant | 5 | 6% |
| Series B | 4 | 5% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 56 | 71% |
| Argentina | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Charlie Bolten | Vice President | 7 | https://shizune.co/investors/profile/charlie-bolten |
| Dan Broderick | Vice President | 2 | https://shizune.co/investors/profile/dan-broderick |
| David Christenson | Entrepreneur In Residence | 0 | https://shizune.co/investors/profile/david-christenson |
| Dennis Schafer | Senior Entrepreneur in Residence | 0 | https://shizune.co/investors/profile/dennis-schafer |
| Nandini Kishore | Entrepreneur in Residence | 0 | https://shizune.co/investors/profile/nandini-kishore |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| IN10T | IN10T is a digital agriculture company, focused on solving farmer adoption challenges in agriculture. We create custom digital and data science solutions for our customers both in agriculture and those investing in agriculture. |  |  | Aug 02, 2023 |  |
| IN10T | IN10T is a digital agriculture company, focused on solving farmer adoption challenges in agriculture. We create custom digital and data science solutions for our customers both in agriculture and those investing in agriculture. |  | Series A | Aug 02, 2023 |  |
| Solis Agrosciences | Solis Agrosciences provides R&D crop development services to Agtech companies. Founded in 2021, Solis Agrosciences is a plant science services company on a mission to accelerate the pace of scientific discovery and commercialization. | $3.1M | Seed | Dec 07, 2022 |  |
| Peptyde Bio | Peptyde Bio is an Agtech startup positioned to become the go-to supplier of new AMPs. | $1.2M | Pre-Seed | Nov 15, 2022 |  |
| Plastomics | Plastomics is a biotechnology startup that focuses in developing the next generation of crops by using chloroplast genetic engineering. Its technology platform is applicable to different crops and traits. Plastomics provides solutions for the many current industry challenges.The company was founded in 2016 and headquartered in St. Louis,Missouri. | $7.1M | Series A | Nov 16, 2021 |  |
| Geneoscopy | Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. | $105M | Series B | Nov 16, 2021 |  |
| Buck Surgical | A medical device company committed to revolutionizing surgical care and expanding patient access to life and limb-preserving treatments. | $16.5K | Grant | Sep 03, 2021 |  |
| Impetus Agriculture | Impetus Agriculture focuses on developing multiple topical or transgenic insect control products. Products that are safe, effective, and sustainable. Products that are not subject to the same insect resistance that has developed in current commercial products. | $1M | Seed | Jun 04, 2021 |  |
| SentiAR | SentiAR is digital health, software device company adding a new dimension to clinical practice in interventional procedures. Spun out of Washington University, we are developing the first 3D visualization platform using real-time holography of the patient's anatomy and catheter location, "floating" over the patients, with a goal toprovide the clinician and patient a faster, safer delivery of care.SentiAR’s mission is to transform the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, “floating” over the patient.The visualization is fully controllable “hands-free” by the clinician, providing an ergonomic breakthrough for the treatment and analysis of cardiac arrhythmias within an interventional catheter lab environment. SentiAR is developing the platform for eventual FDA submission. | $5.1M | Series A | Apr 13, 2021 |  |
| CuriMeta | CuriMeta is a real-world health data firm with a focus on life sciences. |  | Pre-Seed | Dec 01, 2020 |  |

10 of 79 investments shown.

## Co-investors
- [Missouri Technology Corporation](https://shizune.co/investors/profile/missouri-technology-corporation) — VC Fund, 21 deals together
- [Cultivation Capital](https://shizune.co/investors/profile/cultivation-capital) — VC Fund, 16 deals together
- [St. Louis Arch Angels](https://shizune.co/investors/profile/st-louis-arch-angels) — VC Fund, 12 deals together
- [The Yield Lab](https://shizune.co/investors/profile/the-yield-lab) — VC Fund, 8 deals together
- [iSelect Fund](https://shizune.co/investors/profile/iselectfund) — VC Fund, 7 deals together
- [Helix Fund](https://shizune.co/investors/profile/helix-fund) — VC Fund, 4 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does BioGenerator invest in?

BioGenerator invests primarily in Biotechnology, Health Care and Agriculture startups, most often at Seed and Series A stage. Most of the 79 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact BioGenerator?

Public channels for BioGenerator include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at BioGenerator?

The team at BioGenerator includes Charlie Bolten (Vice President), Dan Broderick (Vice President) and David Christenson (Entrepreneur In Residence), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co